Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries

We are analyzing https://link.springer.com/article/10.1186/bcr1649.

Title:
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers | Breast Cancer Research
Description:
Introduction Basal-phenotype or basal-like breast cancers are characterized by basal epithelium cytokeratin (CK5/14/17) expression, negative estrogen receptor (ER) status and distinct gene expression signature. We studied the clinical and biological features of the basal-phenotype tumors determined by immunohistochemistry (IHC) and cDNA microarrays especially within the ER-negative subgroup. Methods IHC was used to evaluate the CK5/14 status of 445 stage II breast cancers. The gene expression signature of the CK5/14 immunopositive tumors was investigated within a subset (100) of the breast tumors (including 50 ER-negative tumors) with a cDNA microarray. Survival for basal-phenotype tumors as determined by CK5/14 IHC and gene expression signature was assessed. Results From the 375 analyzable tumor specimens, 48 (13%) were immunohistochemically positive for CK5/14. We found adverse distant disease-free survival for the CK5/14-positive tumors during the first years (3 years hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.17 to 4.24, p = 0.01; 5 years HR 1.80, 95% CI 1.02 to 3.15, p = 0.04) but the significance was lost at the end of the follow-up period (10 years HR 1.43, 95% CI 0.84 to 2.43, p = 0.19). Gene expression profiles of immunohistochemically determined CK5/14-positive tumors within the ER-negative tumor group implicated 1,713 differently expressed genes (p < 0.05). Hierarchical clustering analysis with the top 500 of these genes formed one basal-like and a non-basal-like cluster also within the ER-negative tumor entity. A highly concordant classification could be constructed with a published gene set (Sorlie
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Science
  • Movies

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💾}

We find it hard to spot revenue streams.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

tumors, gene, breast, expression, basal, basallike, cancer, pubmed, article, tumor, genes, ernegative, google, scholar, cas, analysis, data, status, ckpositive, cluster, set, cytokeratin, survival, basalphenotype, top, file, cancers, ihc, microarray, immunohistochemically, receptor, signature, classification, list, central, clinical, negative, cells, study, colleagues, figure, subgroup, years, intrinsic, cknegative, prognostic, cell, usa, res, phenotype,

Topics {✒}

estrogen-receptor-negative breast cancers estrogen-receptor-negative breast tumors distant disease-free survival abd el-rehim dm microarray-analysis-based classifiers agreed estrogen receptor status negative estrogen receptor ck5/ck14/p63 antibody cocktail hypothesis-generating scientific research lymph-node-positive disease superimposed kaplan-meier curves article download pdf er-negative breast cancers abd el-rehim prognostically distinct entity ck5/14-negative tumor groups swiss-prot annotation contained er-negative tumor entity vector-specific primers essentially immunohistochemically predefined ck5/14-positive node-negative invasive carcinomas estrogen receptor full size image reis-filho js erbb2+/er- tumor groups basal cytokeratin-negative tumors er-negative tumor subgroup membrane-bound cellular localization immunohistochemically ck5/14-negative tumors strong er-related signal basal cytokeratin-immunopositive tumors c-kit-expressing tumors basal-phenotype breast cancer van de rijn basal cytokeratin-positive tumors ck5/14-negative tumors categorized genome-wide expression patterns immunohistochemically ck5/14-positive tumors microarray-based gene data estrogen-positive tumors gene-expression-based classification basal er-negative tumors basal-phenotype breast tumors malignant breast disease seinÀjoki central hospital hormone receptor analysis poorly measured/expressed spots human breast carcinoma additional ck5/14-negative tumors misclassified ck5/14-negative tumors

Questions {❓}

  • Birmbaum D, Bertucci F, Ginestier C, Tagett R, Jacquemier J, Charafe-Jauffret E: Basal and luminal breast cancer: basic or luminous?
  • Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt P, Boecker W, Buerger H: The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?

Schema {đŸ—ș}

WebPage:
      mainEntity:
         headline:Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
         description:Basal-phenotype or basal-like breast cancers are characterized by basal epithelium cytokeratin (CK5/14/17) expression, negative estrogen receptor (ER) status and distinct gene expression signature. We studied the clinical and biological features of the basal-phenotype tumors determined by immunohistochemistry (IHC) and cDNA microarrays especially within the ER-negative subgroup. IHC was used to evaluate the CK5/14 status of 445 stage II breast cancers. The gene expression signature of the CK5/14 immunopositive tumors was investigated within a subset (100) of the breast tumors (including 50 ER-negative tumors) with a cDNA microarray. Survival for basal-phenotype tumors as determined by CK5/14 IHC and gene expression signature was assessed. From the 375 analyzable tumor specimens, 48 (13%) were immunohistochemically positive for CK5/14. We found adverse distant disease-free survival for the CK5/14-positive tumors during the first years (3 years hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.17 to 4.24, p = 0.01; 5 years HR 1.80, 95% CI 1.02 to 3.15, p = 0.04) but the significance was lost at the end of the follow-up period (10 years HR 1.43, 95% CI 0.84 to 2.43, p = 0.19). Gene expression profiles of immunohistochemically determined CK5/14-positive tumors within the ER-negative tumor group implicated 1,713 differently expressed genes (p &lt; 0.05). Hierarchical clustering analysis with the top 500 of these genes formed one basal-like and a non-basal-like cluster also within the ER-negative tumor entity. A highly concordant classification could be constructed with a published gene set (Sorlie's intrinsic gene set, concordance 90%). Both gene sets identified a basal-like cluster that included most of the CK5/14-positive tumors, but also immunohistochemically CK5/14-negative tumors. Within the ER-negative tumor entity there was no survival difference between the non-basal and basal-like tumors as identified by immunohistochemical or gene-expression-based classification. Basal cytokeratin-positive tumors have a biologically distinct gene expression signature from other ER-negative tumors. Even if basal cytokeratin expression predicts early relapse among non-selected tumors, the clinical outcome of basal tumors is similar to non-basal ER-negative tumors. Immunohistochemically basal cytokeratin-positive tumors almost always belong to the basal-like gene expression profile, but this cluster also includes few basal cytokeratin-negative tumors.
         datePublished:2007-01-31T00:00:00Z
         dateModified:2007-01-31T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr1649
         keywords:
            Estrogen Receptor Status
            Basal Cytokeratin
            Negative Estrogen Receptor Status
            Receptor Protein Signaling Pathway
            Distinct Gene Expression Signature
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig4_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:9
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mervi Jumppanen
               affiliation:
                     name:SeinĂ€joki Central Hospital
                     address:
                        name:Department of Pathology, SeinĂ€joki Central Hospital, SeinĂ€joki, Finland
                        type:PostalAddress
                     type:Organization
                     name:University and University Hospital of Tampere
                     address:
                        name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Sofia Gruvberger-Saal
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:PĂ€ivikki Kauraniemi
               affiliation:
                     name:University and University Hospital of Tampere
                     address:
                        name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Minna Tanner
               affiliation:
                     name:University and University Hospital of Tampere
                     address:
                        name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                        type:PostalAddress
                     type:Organization
                     name:Tampere University Hospital
                     address:
                        name:Department of Oncology, Tampere University Hospital, Tampere, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:PĂ€r-Ola Bendahl
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mikael Lundin
               affiliation:
                     name:University of Helsinki
                     address:
                        name:Biomedical Informatics group, Department of Oncology, University of Helsinki, Helsinki, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Morten Krogh
               affiliation:
                     name:Lund University
                     address:
                        name:Department of Theoretical Physics, Lund University, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pasi Kataja
               affiliation:
                     name:University and University Hospital of Tampere
                     address:
                        name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Åke Borg
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:MĂ„rten Fernö
               affiliation:
                     name:University of Lund
                     address:
                        name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jorma Isola
               affiliation:
                     name:University and University Hospital of Tampere
                     address:
                        name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
      description:Basal-phenotype or basal-like breast cancers are characterized by basal epithelium cytokeratin (CK5/14/17) expression, negative estrogen receptor (ER) status and distinct gene expression signature. We studied the clinical and biological features of the basal-phenotype tumors determined by immunohistochemistry (IHC) and cDNA microarrays especially within the ER-negative subgroup. IHC was used to evaluate the CK5/14 status of 445 stage II breast cancers. The gene expression signature of the CK5/14 immunopositive tumors was investigated within a subset (100) of the breast tumors (including 50 ER-negative tumors) with a cDNA microarray. Survival for basal-phenotype tumors as determined by CK5/14 IHC and gene expression signature was assessed. From the 375 analyzable tumor specimens, 48 (13%) were immunohistochemically positive for CK5/14. We found adverse distant disease-free survival for the CK5/14-positive tumors during the first years (3 years hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.17 to 4.24, p = 0.01; 5 years HR 1.80, 95% CI 1.02 to 3.15, p = 0.04) but the significance was lost at the end of the follow-up period (10 years HR 1.43, 95% CI 0.84 to 2.43, p = 0.19). Gene expression profiles of immunohistochemically determined CK5/14-positive tumors within the ER-negative tumor group implicated 1,713 differently expressed genes (p &lt; 0.05). Hierarchical clustering analysis with the top 500 of these genes formed one basal-like and a non-basal-like cluster also within the ER-negative tumor entity. A highly concordant classification could be constructed with a published gene set (Sorlie's intrinsic gene set, concordance 90%). Both gene sets identified a basal-like cluster that included most of the CK5/14-positive tumors, but also immunohistochemically CK5/14-negative tumors. Within the ER-negative tumor entity there was no survival difference between the non-basal and basal-like tumors as identified by immunohistochemical or gene-expression-based classification. Basal cytokeratin-positive tumors have a biologically distinct gene expression signature from other ER-negative tumors. Even if basal cytokeratin expression predicts early relapse among non-selected tumors, the clinical outcome of basal tumors is similar to non-basal ER-negative tumors. Immunohistochemically basal cytokeratin-positive tumors almost always belong to the basal-like gene expression profile, but this cluster also includes few basal cytokeratin-negative tumors.
      datePublished:2007-01-31T00:00:00Z
      dateModified:2007-01-31T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr1649
      keywords:
         Estrogen Receptor Status
         Basal Cytokeratin
         Negative Estrogen Receptor Status
         Receptor Protein Signaling Pathway
         Distinct Gene Expression Signature
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1649/MediaObjects/13058_2006_1614_Fig4_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:9
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mervi Jumppanen
            affiliation:
                  name:SeinĂ€joki Central Hospital
                  address:
                     name:Department of Pathology, SeinĂ€joki Central Hospital, SeinĂ€joki, Finland
                     type:PostalAddress
                  type:Organization
                  name:University and University Hospital of Tampere
                  address:
                     name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Sofia Gruvberger-Saal
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:PĂ€ivikki Kauraniemi
            affiliation:
                  name:University and University Hospital of Tampere
                  address:
                     name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Minna Tanner
            affiliation:
                  name:University and University Hospital of Tampere
                  address:
                     name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                     type:PostalAddress
                  type:Organization
                  name:Tampere University Hospital
                  address:
                     name:Department of Oncology, Tampere University Hospital, Tampere, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:PĂ€r-Ola Bendahl
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mikael Lundin
            affiliation:
                  name:University of Helsinki
                  address:
                     name:Biomedical Informatics group, Department of Oncology, University of Helsinki, Helsinki, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Morten Krogh
            affiliation:
                  name:Lund University
                  address:
                     name:Department of Theoretical Physics, Lund University, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pasi Kataja
            affiliation:
                  name:University and University Hospital of Tampere
                  address:
                     name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Åke Borg
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:MĂ„rten Fernö
            affiliation:
                  name:University of Lund
                  address:
                     name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jorma Isola
            affiliation:
                  name:University and University Hospital of Tampere
                  address:
                     name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:9
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:SeinĂ€joki Central Hospital
      address:
         name:Department of Pathology, SeinĂ€joki Central Hospital, SeinĂ€joki, Finland
         type:PostalAddress
      name:University and University Hospital of Tampere
      address:
         name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University and University Hospital of Tampere
      address:
         name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
         type:PostalAddress
      name:University and University Hospital of Tampere
      address:
         name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
         type:PostalAddress
      name:Tampere University Hospital
      address:
         name:Department of Oncology, Tampere University Hospital, Tampere, Finland
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University of Helsinki
      address:
         name:Biomedical Informatics group, Department of Oncology, University of Helsinki, Helsinki, Finland
         type:PostalAddress
      name:Lund University
      address:
         name:Department of Theoretical Physics, Lund University, Lund, Sweden
         type:PostalAddress
      name:University and University Hospital of Tampere
      address:
         name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University of Lund
      address:
         name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
         type:PostalAddress
      name:University and University Hospital of Tampere
      address:
         name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mervi Jumppanen
      affiliation:
            name:SeinĂ€joki Central Hospital
            address:
               name:Department of Pathology, SeinĂ€joki Central Hospital, SeinĂ€joki, Finland
               type:PostalAddress
            type:Organization
            name:University and University Hospital of Tampere
            address:
               name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Sofia Gruvberger-Saal
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:PĂ€ivikki Kauraniemi
      affiliation:
            name:University and University Hospital of Tampere
            address:
               name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
               type:PostalAddress
            type:Organization
      name:Minna Tanner
      affiliation:
            name:University and University Hospital of Tampere
            address:
               name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
               type:PostalAddress
            type:Organization
            name:Tampere University Hospital
            address:
               name:Department of Oncology, Tampere University Hospital, Tampere, Finland
               type:PostalAddress
            type:Organization
      name:PĂ€r-Ola Bendahl
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Mikael Lundin
      affiliation:
            name:University of Helsinki
            address:
               name:Biomedical Informatics group, Department of Oncology, University of Helsinki, Helsinki, Finland
               type:PostalAddress
            type:Organization
      name:Morten Krogh
      affiliation:
            name:Lund University
            address:
               name:Department of Theoretical Physics, Lund University, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Pasi Kataja
      affiliation:
            name:University and University Hospital of Tampere
            address:
               name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
               type:PostalAddress
            type:Organization
      name:Åke Borg
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:MĂ„rten Fernö
      affiliation:
            name:University of Lund
            address:
               name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Jorma Isola
      affiliation:
            name:University and University Hospital of Tampere
            address:
               name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Pathology, SeinĂ€joki Central Hospital, SeinĂ€joki, Finland
      name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
      name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
      name:Department of Oncology, Tampere University Hospital, Tampere, Finland
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Biomedical Informatics group, Department of Oncology, University of Helsinki, Helsinki, Finland
      name:Department of Theoretical Physics, Lund University, Lund, Sweden
      name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Department of Oncology, Clinical Sciences, University of Lund, Lund, Sweden
      name:Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland

External Links {🔗}(181)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Foundation
  • Prism.js

5.12s.